Catheter Robotics has completed the acquisition of a new product line to be named VIVO. The line is a computerised three-dimensional cardiac-mapping system showing electrical activation of the ventricles of the heart. VIVO stands for “view into ventricular onset”.
In conjunction with the introduction of VIVO and moving into multiple product lines, CRI has chosen to change its name from Catheter Robotics to Catheter Precision. Both the Amigo and VIVO products are oriented towards providing precision for catheter procedures in cardiac electrophysiology including both atrial fibrillation and ventricular arrhythmias.
Missiaen Huck, director of Marketing of CRI comments, “Our new VIVO technology is for catheter treatment of ventricular arrhythmias, a disease treated generally by an expensive implantable defibrillator or by the lengthy catheter ablation procedures in a small number of centers. Our technology should allow the catheter procedures to be accepted and used on a general basis, even in the community hospitals.”
VIVO is intended to allow physicians to accurately pinpoint the origin of a ventricular arrhythmia. The company intends to seek US Food and Drug Administration approval later this year.
